Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Related Keywords

,Aromatase Inhibitor Resistant Hormone ,Human Epidermal Growth Factor Receptor ,Advanced Breast Cancer ,Breast Cancer ,Hr Breast Cancer ,Her2 Breast Cancer ,Capivasertib ,Fulvestrant ,Capitello ,Capitello Trial ,Capitello 291 ,Jcdk4 6 Inhibitor ,Pik3ca Alteration ,Akt1 Alteration ,Pten Alteration ,Capivasertib Adverse Events ,Adverse Events ,Fulvestrant Capivasertib ,Fulvestrant Adverse Events ,Aromatase Inhibitor ,Aromatase Inhibitor Resistant ,